Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial

Published:2021-02 Issue:1 Volume:21 Page:80-91.e7
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Chan Arlene,Moy Beverly,Mansi Janine,Ejlertsen Bent^ORCID,Holmes Frankie Ann,Chia Stephen,Iwata Hiroji,Gnant Michael,Loibl Sibylle,Barrios Carlos H.,Somali Isil,Smichkoska Snezhana^ORCID,Martinez Noelia,Alonso Mirta Garcia,Link John S.,Mayer Ingrid A.,Cold Søren,Murillo Serafin Morales,Senecal Francis,Inoue Kenichi,Ruiz-Borrego Manuel,Hui Rina,Denduluri Neelima,Patt Debra,Rugo Hope S.,Johnston Stephen R.D.,Bryce Richard,Zhang Bo,Xu Feng^ORCID,Wong Alvin,Martin Miguel^ORCID

Funder

Puma Biotechnology Inc

NanoString

Roche

Novartis

Oncology-Venture

AstraZeneca

Genentech

Genomic Health

Chugai Pharma

Daiichi-Sankyo

Eisai

Kyowa Hakko Kirin

Lilly Japan,

Pfizer

Bayer

GlaxoSmithKline

MSD

Abbvie

Amgen

Celgene

Teva

Vifor

Astellas

BMS

Covance

Lilly

Medivation

Merck Serono

PharmaMar

Daiichi

Macrogenics

Merck

Immunomedics

OBI

Odonate

Seattle Genetics

Sermonix

Eli Lilly

Puma Biotechnology

Miller Medical Communications

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference30 articles.

1. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer;Piccart-Gebhart;N Engl J Med,2005

2. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer;Romond;N Engl J Med,2005

3. Adjuvant trastuzumab in HER2-positive breast cancer;Slamon;N Engl J Med,2011

4. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial;Goldhirsch;Lancet,2013

5. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial;Piccart-Gebhart;J Clin Oncol,2016

Cited by 162 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthetic routes and clinical application of Small-Molecule HER2 inhibitors for cancer therapy;Bioorganic Chemistry;2024-10

2. Neratinib safety evaluation: real-world adverse event analysis from the FAERS database;Frontiers in Pharmacology;2024-09-13

3. HER2-CD3-Fc Bispecific Antibody-Encoding mRNA Delivered by Lipid Nanoparticles Suppresses HER2-Positive Tumor Growth;Vaccines;2024-07-21

4. Tailoring neoadjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations;Cancer;2024-07-10

5. Consenso mexicano de cáncer mamario. Manejo del cáncer de mama temprano;Gaceta Mexicana de Oncolog�a;2024-06-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3